(Q35941081)

11 August 2017

Updated recommendations from the Canadian National Consensus Meeting on HER2/neu testing in breast cancer (English)

1 reference

11 August 2017

Hanna W

1

1 reference

11 August 2017

O'malley FP

2

1 reference

11 August 2017

Barnes P

3

1 reference

11 August 2017

Berendt R

4

1 reference

11 August 2017

Gaboury L

5

1 reference

11 August 2017

Magliocco A

6

1 reference

11 August 2017

Pettigrew N

7

1 reference

11 August 2017

Robertson S

8

1 reference

11 August 2017

Sengupta S

9

1 reference

11 August 2017

Têtu B

10

1 reference

11 August 2017

Thomson T

11

1 reference

11 August 2017

language of work or name

1 reference

1 August 2007

1 reference

11 August 2017

1 reference

11 August 2017

14

1 reference

11 August 2017

4

1 reference

11 August 2017

149-153

1 reference

Creative Commons Attribution 4.0 International

11 August 2017

start time

1 August 2007

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

cites work

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1948868

Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1948868

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1948868

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1948868

Best Practice No 176: Updated recommendations for HER2 testing in the UK

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1948868

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1948868

HER2 and responsiveness of breast cancer to adjuvant chemotherapy.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1948868

HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1948868

HER-2 testing in breast cancer using parallel tissue-based methods

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1948868

Minimum formalin fixation time for consistent estrogen receptor immunohistochemical staining of invasive breast carcinoma

24 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/17710207

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

The product of the human c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/17710207

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.3747/CO.2007.131

1 reference

11 August 2017

1 reference

11 August 2017

PubMed publication ID

17710207

1 reference